Bladder Cancer News and Research

Latest Bladder Cancer News and Research

FDA approves continuation of Phase IIb clinical trial for superficial bladder cancer

Tikcro Technologies Ltd. today announced that BioCancell Therapeutics, Inc., concluded the first 18 patient group treated pursuant to a Phase IIb clinical trial of the drug candidate BC-819 for use in superficial bladder cancer. These patients had not responded to conventional treatment.

3 May 2010

Endo Pharmaceuticals reports 9% increase in first-quarter 2010 revenues

Endo Pharmaceuticals today reported financial results for the first quarter 2010.

30 Apr 2010

A major research initiative to optimize quality of life for cancer survivors

At the age of 12, she was diagnosed with spinal cord cancer, with a nasty tumor sitting at the very base of her spinal cord and getting entangled with spinal nerves.

30 Apr 2010

NeoGenomics first-quarter revenue up 22%

NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services today reported its results for the first quarter 2010.

29 Apr 2010

Scientists develop new way of modifying viruses to seek out and destroy cancer cells

CANCER RESEARCH UK scientists at the University of Leeds have developed a new way of modifying viruses to seek out and destroy cancer cells, according to research published in Gene Therapy today1 (Friday).

23 Apr 2010

New studies on cancer prevention presented at 101st AACR Annual Meeting 2010

Interest in cancer prevention is increasing as scientists continue to learn new information and confirm what was already suspected.

22 Apr 2010

Scientists suggest link between well-cooked meat and increased risk of bladder cancer

US scientists have suggested a link between eating well-done meat and a slightly increased risk of bladder cancer. But a Cancer Research UK spokesperson urged caution over the results.

21 Apr 2010

Meat cooked at high temperatures increases risk of developing bladder cancer

People who eat meat frequently, especially meat that is well done or cooked at high temperatures, may have a higher chance of developing bladder cancer, according to a large study at The University of Texas M. D. Anderson Cancer Center presented at the American Association for Cancer Research 101st Annual Meeting 2010. This risk appears to increase in people with certain genetic variants.

20 Apr 2010

EAU honours urological experts at 25th Anniversary Congress

On 16 April 2010 the European Association of Urology opened its 25th Anniversary Congress. During the ceremony, several urological experts were honoured with awards for the outstanding work they did for the urological community. EAU Secretary General Per-Anders Abrahamsson handed them out.

17 Apr 2010

Updated clinical guidelines presented at EAU Anniversary Congress

A number of updated guidelines are presented at the Anniversary Congress of the European Association of Urology (EAU) held in Barcelona, from 16 through 20 April. The abridged versions - Pocket Guidelines - which are based on the extended text documents will also be available in Barcelona to all EAU members and press.

17 Apr 2010

Early, accurate detection of superficial bladder cancer with Olympus PDD

With Olympus photodynamic diagnosis (PDD), superficial bladder cancer can be detected earlier, easier and more accurately. Bladder cancer is diagnosed by cystoscopy, the endoscopic introduction of a light source through the urethra (transurethral) into the bladder. The imaging technology PDD uses blue light to increase the contrast between tumour tissue (red) and healthy tissue (blue).

From Evident Corporation - Life Sciences 15 Apr 2010

Tengion completes initial 6M common stock public offering

Tengion, Inc., a regenerative medicine company focused on discovering, developing, manufacturing and commercializing neo-organs and neo-tissues, today announced the completion of its initial public offering of 6,000,000 shares of common stock at a price of $5.00 per share. The net proceeds of the offering to Tengion, after deducting underwriting discounts and commissions and estimated offering expenses payable by Tengion, were approximately $26.0 million.

15 Apr 2010

Over 12,000 participants already registered for 25th Anniversary EAU Congress

The upcoming 25th Anniversary EAU Congress in Barcelona from April 16 to 20 promises to be one of the EAU's biggest meetings in recent years with around 12,100 participants already registered to attend the annual urological event.

12 Apr 2010

Spectrum Pharmaceuticals reports $15.7M revenue from ZEVALIN sales in 2009

Spectrum Pharmaceuticals, Inc., a commercial-stage biotechnology company with a primary focus in oncology, today reported financial results for the fourth quarter and fiscal year ended December 31, 2009.

5 Apr 2010

Rigel Pharmaceuticals, AstraZeneca license agreement: Waiting period under Antitrust Improvements Act expires

Rigel Pharmaceuticals, Inc. today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 relating to the license agreement between Rigel and AstraZeneca, the effectiveness of which was contingent on the expiration of the waiting period.

29 Mar 2010

Chinese Patent Office granted new patent for Totobobo mask

The Chinese Patent Office granted a new patent for the innovative Totobobo mask. Considering the increasing difficulties in acquiring a Chinese patent, this comes as a major achievement. The potential sale of Totobobo masks will greatly increase now that the Chinese market has opened to this innovative product.

29 Mar 2010

Æterna Zentaris announces 2009 financial and operating results

Æterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today reported financial and operating results as at and for the fourth quarter and the full year ended December 31, 2009.

24 Mar 2010

Most controversial issues in urology to be discussed in the Annual Congress of EAU

Some of the most controversial issues in urology will be discussed by leading experts during the five-day 25th Annual Congress of the European Association of Urology in the Fira Barcelona congress venue in Barcelona (ES). From April 16 to 20, close to 12,000 participants and 3,000 company representatives are expected to gather in one of the world's biggest annual professional meetings in urology.

17 Mar 2010

Safeguard Scientifics' aggregate partner company revenue rises 46% in 2009

Safeguard Scientifics, Inc., a holding company that builds value in growth-stage life sciences and technology companies, today announced that aggregate revenue of its partner companies for the year was $262 million, up 46% from $179 million in 2008, exceeding the company’s 2009 guidance of $223 million to $243 million, as adjusted to reflect the inclusion of two new partner companies.

11 Mar 2010

Predictive Biosciences to present its novel MADR approach during 2010 GU Symposium

Predictive Biosciences today announced that the Company will be presenting its novel Multi-Analyte Diagnostic Readout approach to the development of a non-invasive, urinary biomarker based assay for the detection of bladder cancer during the 2010 Genitourinary Cancers Symposium, being held March 5-7 in San Francisco.

5 Mar 2010